Regular colorectal cancer (CRC) screening may help
reduce mortality rates and has the potential to save lives¹

The U.S. Preventive Services Task Force (USPSTF) and the American Cancer Society (ACS) both recommend screening patients at average risk for CRC starting at age 45.^1,2

(Grade B recommendation)^1*†

Of the ~44 million average-risk patients
aged 45 and older eligible for CRC screening3:
~19 Million
Screening-eligible patients are aged 45 to 49 years3

Despite the American Cancer Society (ACS) lowering its initial screening age to 45 in 2018²:

Initiating CRC screening at age 45 provides multiple benefits according to projection models, including averted CRC cases, a reduction in CRC-related deaths, and an increase in patient life-years gained.¹

Incidence and severity in patients <50

CRC incidence in younger populations is estimated to increase by 90% by 2030^5‡

Among patients younger than 50 years:

51^%
Increase in the incidence
of CRC since 1994²
52^%
Were diagnosed with more
advanced stages of CRC vs
40% of patients aged 50+ years
(2004-2015)^6§

There is a significant risk in waiting to screen for CRC⁷

0
Symptoms
Many patients with early-stage CRC 

have no symptoms, making proactive 

screening the only way to detect CRC8
~90%
Survival Rate
The 5-year relative survival rate 

(stages I and II)|| is 90%, but when 

diagnosed in stage IV, that number 

drops to 15%7

5-year survival rates by stage of CRC^7,9||:

Unfortunately, more than half of patients are diagnosed with regional or distant disease.^7¶

Financial impact

For each patient 

diagnosed in stage I or II
$57,901
is the average cost of first-year

CRC treatment10#**
For each patient

diagnosed in stage IV
$108,599
Is the average cost of first-year

CRC treatment10**

Screen every eligible patient aged 45 years and older for CRC by helping them overcome their barriers to screening

Regular colorectal cancer (CRC) screening may help reduce mortality rates and has the potential to save lives1

The U.S. Preventive Services Task Force (USPSTF) and the American Cancer Society (ACS) both recommend screening patients at average risk for CRC starting at age 45.1,2

Despite the American Cancer Society (ACS) lowering its initial screening age to 45 in 20182:

CRC incidence in younger populations is estimated to increase by 90% by 20305‡

Among patients younger than 50 years:

There is a significant risk in waiting to screen for CRC7

Unfortunately, more than half of patients are diagnosed with regional or distant disease.7¶

Financial impact

For each patient diagnosed in stage I or II

$57,901

For each patient diagnosed in stage IV

$108,599

Regular colorectal cancer (CRC) screening may help
reduce mortality rates and has the potential to save lives¹

The U.S. Preventive Services Task Force (USPSTF) and the American Cancer Society (ACS) both recommend screening patients at average risk for CRC starting at age 45.^1,2

Despite the American Cancer Society (ACS) lowering its initial screening age to 45 in 2018²:

CRC incidence in younger populations is estimated to increase by 90% by 2030^5‡

There is a significant risk in waiting to screen for CRC⁷

Unfortunately, more than half of patients are diagnosed with regional or distant disease.^7¶

For each patient
diagnosed in stage I or II

For each patient
diagnosed in stage IV